What is Progenra?
Progenra is a biopharmaceutical company dedicated to pioneering new medicines through its innovative UbiPro platform. This platform leverages molecular glues and targeted protein degradation to address critical unmet needs in therapeutic areas such as neurodegenerative diseases, cardiovascular disorders, and metabolic dysfunction. By focusing on the Ubiquitin Proteasome System, Progenra aims to create first-in-class therapeutics that can redefine treatment paradigms and enhance patient care through its advanced drug discovery engine. The company is actively pursuing strategic partnerships to accelerate the development of its promising pipeline.
How much funding has Progenra raised?
Progenra has raised a total of $330K across 2 funding rounds:
Debt
$150K
Debt
$180K
Debt (2020): $150K with participation from PPP
Debt (2021): $180K led by PPP
Key Investors in Progenra
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Progenra?
With its substantial late-stage funding, Progenra is well-positioned to advance its pipeline of transformative therapies. The company's focus on targeted protein degradation and molecular glues aligns with emerging trends in drug discovery, suggesting a strong potential for future growth and market impact. Continued investment will likely fuel further research and development, clinical trials, and potential commercialization efforts, solidifying Progenra's role in addressing complex diseases.
See full Progenra company page
